Physician profile
Joshua Rycus
NPI 1730111287
$12,591.70
in general payments reported to CMS, 2019-2025
34 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 90% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,301 · 2020: $2,167 · 2021: $1,896 · 2022: $1,744 · 2023: $1,545 · 2024: $1,434 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,482.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,204.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,548.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,543.36 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Novo Nordisk INC | $1,259.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $688.27 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $658.65 | 2021-2025 | |
| Pfizer INC. | $465.83 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $452.81 | 2019-2023 | |
| Amarin Pharma, INC. | $386.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $201.25 | 2019-2021 | |
| Amgen INC. | $150.97 | 2019-2023 | Otezla, Repatha |
| Eisai INC. | $143.09 | 2020-2021 | |
| Abbvie INC. | $133.71 | 2019-2025 | Ubrelvy, Vraylar |
| Janssen Pharmaceuticals, INC | $104.68 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $79.05 | 2022-2023 | Quviviq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.85 | 2022-2023 | |
| Abbott Laboratories | $73.34 | 2024-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $57.25 | 2019-2021 | |
| Mylan Specialty L.P. | $49.09 | 2020-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $37.88 | 2019 | |
| Ibsa Pharma INC. | $36.03 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.99 | 2019 | |
| Allergan, INC. | $28.48 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $26.33 | 2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $20.71 | 2021 | |
| Astellas Pharma US INC | $18.43 | 2019 | |
| Optinose US, INC. | $17.64 | 2025 | |
| Nevro Corp. | $16.88 | 2023 | Senza |
| Tolmar, INC. | $16.18 | 2025 | Jatenzo |
| Exact Sciences Corporation | $16.18 | 2024 | Cologuard Collection Kit |
| Acella Pharmaceuticals, LLC | $13.47 | 2025 | NP Thyroid 60 |
| Shire North American Group INC | $13.09 | 2019 | |
| Avion Pharmaceuticals | $12.64 | 2019 | |
| Aytu Biopharma, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Rycus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.